Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVIZOR LACRIFRESH is a brand of lubricating ophthalmic solutions (artificial tears) developed by the Spanish company Avizor and distributed in various markets, including Vietnam by TV TPI. The product line is primarily designed to alleviate symptoms of dry eye syndrome, ocular irritation, and eye fatigue caused by environmental factors, prolonged screen use, or contact lens wear. The flagship formulation, Lacrifresh Moisture, contains 0.1% sodium hyaluronate, a naturally occurring viscoelastic polysaccharide that mimics the properties of the natural tear film to stabilize the precorneal layer and provide long-lasting hydration. Other variants in the line include Lacrifresh Comfort (containing povidone) and Lacrifresh Ocu-Dry (containing higher concentrations of sodium hyaluronate, such as 0.2% or 0.3%). These products are often registered as medical devices or over-the-counter pharmaceutical lubricants depending on the jurisdiction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate (Avizor).